Contribution |
Citation |
Altmetric Badge |
|
Xie X, Lee J, Fuson JA, et al. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. Biomedicines. 2023 Feb 28;11(3):735.
|
|
|
Zhukovsky DS, Soliman P, Liu D, et al. Patient Engagement With Early Stage Advance Care Planning at a Comprehensive Cancer Center. Oncologist. 2023 Feb 27.
|
|
|
Engler A, Butler B, Tewari P. “The Future Redefined” Pediatric, Adolescent and Young Adult College and Career Fair: A Collaborative Symposium to Provide Proactive Education for Oncology Patients and Survivors. J Adolesc Young Adult Oncol. 2023 Feb 24.
|
|
|
Choi E, Becker H, Lu Q, Roth M. Sex differences in comorbid conditions, health behaviors, health care utilization, and health-related quality of life among young adult cancer survivors. Support Care Cancer. 2023 Feb 23;31(3):181.
|
|
|
Yu G, Zhang W, Zhang H, et al. The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases. Res Sq. 2023 Feb 22.
|
|
|
Blumenthaler AN, Robinson KA, Hodge C, et al. Communication Frameworks for Palliative Surgical Consultations: A Randomized Study of Advanced Cancer Patients. Ann Surg. 2023 Feb 21.
|
|
|
Ruiz JI, Lopez-Olivo MA, Geng Y, Suarez-Almazor ME. COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review. J Immunother Precis Oncol. 2023 Feb 22.
|
|
|
Flores Legarreta A, Salvo G, Gonzales NR, Chisholm G, Hillman RT, Frumovitz M. RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study. J Gynecol Oncol. 2023 Feb 9.
|
|
|
Nelson BE, Roszik J, Janku F, et al. BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18;7(1):19.
|
|
|
Zhang S, Kim K-B, Huang Y, et al. CRACD, a gatekeeper restricting proliferation, heterogeneity, and immune evasion of small cell lung cancer. bioRxiv. 2023 Feb 15.
|
|
|
Swartz MC, Robertson MC, Christopherson U, et al. Assessing the Suitability of a Virtual ‘Pink Warrior’ for Older Breast Cancer Survivors during COVID-19: A Pilot Study. Life (Basel). 2023 Feb 18;13(2):574.
|
|
|
Ferri-Borgogno S, Zhu Y, Sheng J, et al. Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res. 2023 Feb 14.
|
|
|
Dasari SK, Joseph R, Umamaheswaran S, et al. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15;24(4):3915.
|
|
|
Liu S, Xie S, Liu W, et al. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq. 2023 Feb 14.
|
|
|
Wang M, Ding Q, Gu J, et al. Breast Cancer with a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer. 2023 Feb 12.
|
|
|
Wei D, Chen D, Mou H, et al. Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. Mol Cancer Ther. 2023 Feb 10.
|
|
|
Patel B, Zhou Y, Babcock RL, et al. STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity. bioRxiv. 2023 Feb 11.
|
|
|
Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med. 2023 Feb 7.
|
|
|
Gordon MJ, Duan Z, Zhao H, et al. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv. 2023 Feb 8.
|
|
|
Barcena AJR, Perez JVD, Damasco JA, et al. Gold Nanoparticles for Monitoring of Mesenchymal Stem Cell–Loaded Bioresorbable Polymeric Wraps for Arteriovenous Fistulas. bioRxiv. 2023 Feb 3.
|
|
|
Frenkel M, David A, Sapire K, Hausner D. Complementary and Integrative Medicine in Pancreatic Cancer. Curr Oncol Rep. 2023 Feb 3.
|
|
|
Ruiz JI, Lopez-Olivo MA, Geng Y, Suarez-Almazor ME. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother Cancer. 2023 Feb;11(2):e006246.
|
|
|
Cho WC, Vanderbeck K, Nagarajan P, et al. SOX11 Is an Effective Discriminatory Marker, When Used in Conjunction With CK20 and TTF1, for Merkel Cell Carcinoma: Comparative Analysis of SOX11, CK20, PAX5, and TTF1 Expression in Merkel Cell Carcinoma and Pulmonary Small Cell Carcinoma. Arch Pathol Lab Med. 2023 Feb 6.
|
|
|
Zou J, Kongtim P, Oran B, et al. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023 Feb 4.
|
|
|
Smith JM, Kapur SK, Mericli AF, Baumann DP, Butler CE. Parastomal hernia repair. Plast Aesthet Res. 2023 Feb;9(10).
|
|
|
Zhang X, Yao J, Niu N, et al. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol. 2023 Feb;36(2):100001.
|
|
|
Meernik C, Jorgensen K, Wu C-F, et al. Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study. Breast Cancer Res Treat. 2023 Feb;198(1):149-158.
|
|
|
Zeng Z, Maiti A, Herbrich S, et al. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer. 2023 Feb 15;129(4):531-540.
|
|
|
Contrera KJ, Gule-Monroe M, Hu MI, et al. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 Jan;33(1):129-132.
|
|
|
An C, Pipia I, Ruiz A-S, et al. The molecular link between obesity and genomic instability in cancer development. Cancer Lett. 2023 Feb 28;555:216035.
|
|